ATE513543T1 - Behandlung von kachexie - Google Patents

Behandlung von kachexie

Info

Publication number: ATE513543T1
Authority: AT; Austria
Prior art keywords: cachexia; treatment; prevention; receptors; tertatolol
Prior art date: 2006-12-05

Application number

AT07824794T

Other languages

English (en)

Inventor

David Cavalla

Original Assignee

Psioxus Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-05

Filing date

2007-12-05

Publication date

2011-07-15

2007-12-05 Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd

2011-07-15 Application granted granted Critical

2011-07-15 Publication of ATE513543T1 publication Critical patent/ATE513543T1/de

Links

206010006895 Cachexia Diseases 0.000 title abstract 2
230000002265 prevention Effects 0.000 abstract 2
AQHHHDLHHXJYJD-AWEZNQCLSA-N (2s)-1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol Chemical compound C1=CC=C2C(OC[C@@H](O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-AWEZNQCLSA-N 0.000 abstract 1
JZQKKSLKJUAGIC-NSHDSACASA-N (S)-(-)-pindolol Chemical compound CC(C)NC[C@H](O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-NSHDSACASA-N 0.000 abstract 1
UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 abstract 1
208000017667 Chronic Disease Diseases 0.000 abstract 1
102000017911 HTR1A Human genes 0.000 abstract 1
101150015707 HTR1A gene Proteins 0.000 abstract 1
HTWFXPCUFWKXOP-UHFFFAOYSA-N Tertatalol Chemical compound C1CCSC2=C1C=CC=C2OCC(O)CNC(C)(C)C HTWFXPCUFWKXOP-UHFFFAOYSA-N 0.000 abstract 1
102000012740 beta Adrenergic Receptors Human genes 0.000 abstract 1
108010079452 beta Adrenergic Receptors Proteins 0.000 abstract 1
229960001035 bopindolol Drugs 0.000 abstract 1
230000009467 reduction Effects 0.000 abstract 1
230000035945 sensitivity Effects 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
229960003352 tertatolol Drugs 0.000 abstract 1
230000004584 weight gain Effects 0.000 abstract 1
235000019786 weight gain Nutrition 0.000 abstract 1
208000016261 weight loss Diseases 0.000 abstract 1
230000004580 weight loss Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Neurology (AREA)
Obesity (AREA)
Diabetes (AREA)
Tropical Medicine & Parasitology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Nutrition Science (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)

AT07824794T 2006-12-05 2007-12-05 Behandlung von kachexie ATE513543T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0624282.0A GB0624282D0 (en)	2006-12-05	2006-12-05	Treatment of cachexia
PCT/GB2007/004644 WO2008068477A1 (en)	2006-12-05	2007-12-05	Treatment of cachexia

Publications (1)

Publication Number	Publication Date
ATE513543T1 true ATE513543T1 (de)	2011-07-15

Family

ID=37671884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07824794T ATE513543T1 (de)	2006-12-05	2007-12-05	Behandlung von kachexie

Country Status (16)

Country	Link
US (1)	US8716325B2 (de)
EP (2)	EP2094254B1 (de)
JP (1)	JP5166437B2 (de)
CN (1)	CN101610760B (de)
AT (1)	ATE513543T1 (de)
AU (1)	AU2007330607B2 (de)
BR (1)	BRPI0720114A8 (de)
CA (1)	CA2671622C (de)
DK (1)	DK2094254T3 (de)
ES (1)	ES2395244T3 (de)
GB (1)	GB0624282D0 (de)
PL (1)	PL2094254T3 (de)
PT (1)	PT2094254E (de)
RU (1)	RU2485950C2 (de)
WO (1)	WO2008068477A1 (de)
ZA (1)	ZA200904704B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0907350D0 (en) *	2009-04-29	2009-06-10	Myotec Therapeutics Ltd	Methods
BR112015001712A2 (pt) *	2012-07-25	2017-07-04	Psioxus Therapeutics Ltd	uso de s-pindolol para o tratamento da caquexia e sarcopenia
HRP20182041T1 (hr)	2013-03-14	2019-02-08	Actimed Therapeutics Ltd	Pripravci oksprenolola za liječenje raka
AU2017224965B2 (en)	2016-02-26	2022-06-30	Actimed Therapeutics Ltd	S-enantiomerically enriched compositions of beta blockers for treating muscle weakness
GB2593902B (en) *	2020-04-07	2022-04-13	Actimed Therapeutics Ltd	Salt of a pharmaceutical compound
GB202114564D0 (en)	2021-10-12	2021-11-24	Actimed Therapeutics Ltd	Oral formulation
WO2025222169A1 (en)	2024-04-19	2025-10-23	Faraday Pharmaceuticals, Inc.	S-oxprenolol for preserving muscle mass, bone density, and cardiac function in weight loss treatments

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5541188A (en) *	1987-09-15	1996-07-30	The Rowett Research Institute	Therapeutic applications of beta-adrenergic agonists
CA1337432C (en)	1988-03-23	1995-10-24	Raymond M. Xhonneux	Method of lowering the blood pressure
US6545040B1 (en) *	1988-03-23	2003-04-08	Janssen Pharmaceutica N.V.	Method of lowering the blood pressure
CA2025398A1 (en)	1989-09-20	1992-03-15	Timothy Gerard Dinan	Diagnosis and treatment of a disorder of the gastrointestinal tract
US5120791A (en)	1990-07-27	1992-06-09	Lisco, Inc.	Golf ball cover compositions
ATE457169T1 (de)	1998-10-15	2010-02-15	Imp Innovations Ltd	Verbindungen für die behandlung von gewichtsverlust
CZ20022410A3 (cs) *	2000-01-31	2003-08-13	Pfizer Products Inc.	Benzoanelované heterocyklylové deriváty nikotinamidu užitečné jako selektivní inhibitory isozymů PDE4
AR030414A1 (es) *	2000-04-03	2003-08-20	Astrazeneca Ab	Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
WO2003065970A2 (en) *	2001-02-20	2003-08-14	Royal College Of Surgeons Ie	Treatment of fibromyalgia and related fatigue syndromes using pindolol
US6670140B2 (en) *	2001-03-06	2003-12-30	The Procter & Gamble Company	Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
EP1793818A2 (de)	2004-09-17	2007-06-13	Neurocure Ltd.	Pindolol zur behandlung des prämenstruellen syndroms und von prämenstrueller dysphorie
CA2580694A1 (en)	2004-09-23	2006-03-30	Alexander Michalow	Methods for regulating neurotransmitter systems by inducing counteradaptations
EP1990049A3 (de)	2005-03-21	2008-11-26	Vicus Therapeutics SPE 1, LLC	Kombinationstherapie von Beta-Blockern und nicht steroidalen antiinflammatorischen Antiphlogistika/Antirheumatika (NSAR)
US8080528B2 (en) *	2005-12-22	2011-12-20	The Releef Initiative	Compositions and methods for treatment of cachexia
CA2643802A1 (en)	2006-02-27	2007-09-07	Alexander Michalow	Methods for regulating neurotransmitter systems by inducing counteradaptations
EP2081569A2 (de)	2006-11-09	2009-07-29	Boehringer Ingelheim International GmbH	Kombinationstherapie mit sglt-2-hemmern und ihren pharmazeutischen zusammensetzungen
WO2008129308A2 (en)	2007-04-24	2008-10-30	Acacia Pharma Limited	Drug combination and its use in the treatment of muscle loss
EP2259844A4 (de)	2008-03-05	2012-02-01	Vicus Therapeutics Llc	Zusammensetzungen und verfahren für mukositis- und onkologische therapien

2006
- 2006-12-05 GB GBGB0624282.0A patent/GB0624282D0/en not_active Ceased
2007
- 2007-12-05 RU RU2009125548/15A patent/RU2485950C2/ru active
- 2007-12-05 DK DK07824794.7T patent/DK2094254T3/da active
- 2007-12-05 WO PCT/GB2007/004644 patent/WO2008068477A1/en not_active Ceased
- 2007-12-05 PL PL07824794T patent/PL2094254T3/pl unknown
- 2007-12-05 PT PT07824794T patent/PT2094254E/pt unknown
- 2007-12-05 EP EP07824794A patent/EP2094254B1/de active Active
- 2007-12-05 US US12/312,756 patent/US8716325B2/en active Active
- 2007-12-05 EP EP11001660.7A patent/EP2359822B1/de active Active
- 2007-12-05 BR BRPI0720114A patent/BRPI0720114A8/pt not_active Application Discontinuation
- 2007-12-05 ES ES07824794T patent/ES2395244T3/es active Active
- 2007-12-05 AU AU2007330607A patent/AU2007330607B2/en active Active
- 2007-12-05 AT AT07824794T patent/ATE513543T1/de active
- 2007-12-05 CA CA2671622A patent/CA2671622C/en active Active
- 2007-12-05 JP JP2009539801A patent/JP5166437B2/ja active Active
- 2007-12-05 CN CN2007800446415A patent/CN101610760B/zh active Active
2009
- 2009-07-03 ZA ZA200904704A patent/ZA200904704B/xx unknown

Also Published As

Publication number	Publication date
JP5166437B2 (ja)	2013-03-21
BRPI0720114A2 (pt)	2014-04-15
EP2359822B1 (de)	2016-08-03
EP2359822A1 (de)	2011-08-24
PT2094254E (pt)	2011-09-19
JP2010511685A (ja)	2010-04-15
CA2671622A1 (en)	2008-06-12
PL2094254T3 (pl)	2011-12-30
RU2009125548A (ru)	2011-01-20
RU2485950C2 (ru)	2013-06-27
BRPI0720114A8 (pt)	2016-01-19
CA2671622C (en)	2015-01-27
CN101610760A (zh)	2009-12-23
AU2007330607A1 (en)	2008-06-12
DK2094254T3 (da)	2011-10-03
ES2395244T3 (es)	2013-02-11
US20100292270A1 (en)	2010-11-18
WO2008068477A1 (en)	2008-06-12
EP2094254B1 (de)	2011-06-22
ZA200904704B (en)	2010-05-26
CN101610760B (zh)	2012-09-26
EP2094254A1 (de)	2009-09-02
US8716325B2 (en)	2014-05-06
GB0624282D0 (en)	2007-01-10
AU2007330607B2 (en)	2013-02-07

Legal Events

Date

Code

Title

Description

2011-12-15

UEP

Publication of translation of european patent specification

Ref document number: 2094254

Country of ref document: EP

Publication	Publication Date	Title
NO20090623L (no)	2009-03-20	Forbindelser for behandling av proliferative lidelser
EA200800555A1 (ru)	2008-08-29	Производные ксантина в качестве селективных агонистов hm74a
EA200970447A1 (ru)	2009-10-30	Соединения и композиции в качестве ингибиторов протеинкиназы
DK2094254T3 (da)	2011-10-03	Behandling af kakeksi
NO20091260L (no)	2009-03-26	Kombinasjonsbehandling for diabetes mellitus
ATE468332T1 (de)	2010-06-15	Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate
EA200900828A1 (ru)	2009-12-30	Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA200901442A1 (ru)	2010-06-30	Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
NO20074943L (no)	2007-10-01	Roflumilast for behandlingen av diabetes mellitus
ATE449097T1 (de)	2009-12-15	Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
DE602007008524D1 (de)	2010-09-30	Spiroimidazol-derivate als ppar-modulatoren
CY1115710T1 (el)	2017-01-25	Ρευστο παρασκευασμα που περιλαμβανει ενα συμπλοκο πιμοβενδανης και κυκλοδεξτρινης
PY0723043A (es)	2012-11-01	Derivados de N-(Amino-heteroaril)-1H-Indol-2-carboxamidas, su preparación y su aplicación en terapéutica.
EA200970302A1 (ru)	2009-10-30	Тиофенпиразолопиримидиновые соединения
UA98839C2 (en)	2012-06-25	N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CY1117174T1 (el)	2017-04-05	ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
EA201001747A1 (ru)	2011-08-30	Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
WO2009071689A3 (de)	2009-07-23	5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
TW200611695A (en)	2006-04-16	Pyrrolopyridine derivatives
TW200740429A (en)	2007-11-01	Methods and dosage forms for reducing side effects of carbamate compounds
DK1610787T3 (da)	2008-06-02	Synergistisk kombination der omfatter roflumilast og et antikolinergt middel der er valgt blandt tiotropiumsalte til behandling af respiratoriske sygdomme
UA106200C2 (uk)	2014-08-11	Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
EA200601699A1 (ru)	2007-04-27	Замещённые фенокси- и фенилтиопроизводные для лечения пролиферативных нарушений
WO2008021048A3 (en)	2008-09-04	Adp-ribosyltransferase based methods and compositions
UY31146A1 (es)	2009-01-30	Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene